BeiGene Ltd (FRA:49BA)
€ 151 -1 (-0.66%) Market Cap: 15.79 Bil Enterprise Value: 14.17 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 01:20PM GMT
Release Date Price: €197 (+10.67%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Okay. Thank you, everyone. Appreciate that. With that, happy to have with me Mr. Mehrdad Mobasher, CMO of Hematology from BeiGene; and Mark Lanasa, CMO of Solid Tumors for BeiGene. Thank you both for joining us.

Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology

Appreciate it.

Mark Lanasa
BeiGene, Ltd. - Senior VP & Chief Medical Officer for Solid Tumors

Appreciate it.

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Before we get into any pipeline-related and Brukinsa-related Q&A, I thought it might be good just to level set for the audience, if you could both just provide a quick overview of what you think some of the key inflection points have been across your respective areas of work at BeiGene for this year?

Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology

So maybe I'll start first with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot